+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030- Product Image
Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030- Product Image
Sale

Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014922
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Alizapride is solidifying its position as a critical antiemetic therapy, answering urgent healthcare needs across clinical environments. As market demand shifts with innovations and ongoing regulatory changes in the global healthcare sector, senior stakeholders require actionable insight to navigate this evolving landscape.

Market Snapshot: Alizapride Market Size & Growth

The Alizapride Market grew from USD 7.28 billion in 2024 to USD 7.84 billion in 2025. It is expected to continue growing at a CAGR of 7.48%, reaching USD 11.23 billion by 2030. This robust trajectory highlights Alizapride’s relevance for providers seeking consistent, evidence-based outcomes in both acute and chronic care settings.

Scope & Segmentation

Our comprehensive research covers the full spectrum of the Alizapride market, segmenting data to support targeted strategy for manufacturers, distributors, and end-users.

  • Route of Administration: Intramuscular (multi-dose and single-dose), Intravenous (bolus infusion and continuous infusion), and Oral (solution and tablet) approaches directly affect dosing flexibility and care settings.
  • Distribution Channel: Hospital pharmacies in both private and public institutions, Online pharmacies (serving direct-to-patient and third-party platforms), and Retail pharmacies (chain and independent) shape market accessibility and distribution efficiency.
  • End User: Clinics (general and oncology), Home care (nurse-administered and self-administered), and Hospitals (private and public) represent key points of Alizapride utilization.
  • Therapeutic Indication: Chemotherapy-induced nausea (adult and pediatric segments), Postoperative (day-surgery and inpatient), and Pregnancy-related nausea (hyperemesis gravidarum, morning sickness) highlight the treatment’s versatility.
  • Geographies: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (major European nations and select Middle East, Africa markets), and Asia-Pacific (China, India, Japan, Australia, and others). Each region is further segmented with nuanced analysis of influential sub-markets.
  • Key Companies: Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Hikma Pharmaceuticals PLC, Viatris Inc., Cipla Limited, Aspen Pharmacare Holdings Limited, among others driving innovation and competitive strategies.

Key Takeaways for Senior Stakeholders

  • Heightened focus on patient-centric care is increasing the relevance of flexible antiemetic regimens, underpinning the need for diverse administration routes and robust supply chains.
  • Shifts toward value-based healthcare compel providers to adopt therapies like Alizapride, which balance reliable symptom relief with healthcare resource optimization.
  • Expanding digitalization, including the growth of online pharmacies and telehealth, is transforming distribution, supporting both remote and traditional prescribing models.
  • Demographic factors—such as aging populations and the increase in procedural and chemotherapeutic interventions—are amplifying demand for dependable antiemetic treatments.
  • Manufacturers leveraging partnerships and technology-driven process efficiencies are positioning themselves to respond quickly to emerging market and regulatory developments.
  • Success in this market increasingly depends on adaptability, regional differentiation, and ongoing clinician engagement as healthcare delivery and patient preferences evolve.

Tariff Impact on Alizapride Market Dynamics

The implementation of higher U.S. tariffs on raw materials and pharmaceutical intermediates since early 2025 has elevated manufacturing and distribution costs for Alizapride. Market participants have responded through proactive procurement diversification and process optimization, absorbing cost volatility while maintaining a stable supply chain. Continuous operational agility remains essential as policy landscapes evolve.

Market Research Methodology & Data Sources

Findings are based on a multi-phased approach, integrating primary interviews with clinicians, distributors, and regulatory specialists, and systematic secondary research. Quantitative insights were validated using a combination of proprietary data, public datasets, and rigorous expert review at each stage.

Why This Report Matters

  • Facilitate informed investment and operational decisions with a data-driven understanding of market behaviors, risks, and opportunities specific to the Alizapride sector.
  • Identify actionable avenues for product innovation, partnership, and regional growth amid changing therapeutic guidelines and competitive pressures.

Conclusion

The Alizapride market continues to experience strategic transformation shaped by regulatory, demographic, and technological influences. Forward-thinking stakeholders can leverage these insights to steer resource planning and accelerate competitive advantage in antiemetic care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alizapride Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular
8.2.1. Multi Dose
8.2.2. Single Dose
8.3. Intravenous
8.3.1. Bolus Infusion
8.3.2. Continuous Infusion
8.4. Oral
8.4.1. Oral Solution
8.4.2. Tablet
9. Alizapride Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Private Hospitals
9.2.2. Public Hospitals
9.3. Online Pharmacies
9.3.1. Direct To Patient
9.3.2. Third Party Marketplaces
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Alizapride Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. General
10.2.2. Oncology
10.3. Home Care
10.3.1. Nurse Administered
10.3.2. Self Administered
10.4. Hospitals
10.4.1. Private
10.4.2. Public
11. Alizapride Market, by Therapeutic Indication
11.1. Introduction
11.2. Chemotherapy Induced Nausea
11.2.1. Adult
11.2.2. Pediatric
11.3. Postoperative Nausea
11.3.1. Day Surgery
11.3.2. Inpatient Surgery
11.4. Pregnancy Related Nausea
11.4.1. Hyperemesis Gravidarum
11.4.2. Morning Sickness
12. Americas Alizapride Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Alizapride Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Alizapride Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Sandoz International GmbH
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Sun Pharmaceutical Industries Limited
15.3.4. Dr. Reddy's Laboratories Limited
15.3.5. Hikma Pharmaceuticals PLC
15.3.6. Viatris Inc.
15.3.7. Cipla Limited
15.3.8. Aspen Pharmacare Holdings Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ALIZAPRIDE MARKET MULTI-CURRENCY
FIGURE 2. ALIZAPRIDE MARKET MULTI-LANGUAGE
FIGURE 3. ALIZAPRIDE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALIZAPRIDE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALIZAPRIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ALIZAPRIDE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ALIZAPRIDE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALIZAPRIDE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALIZAPRIDE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALIZAPRIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALIZAPRIDE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALIZAPRIDE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALIZAPRIDE MARKET SIZE, BY BOLUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALIZAPRIDE MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALIZAPRIDE MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALIZAPRIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALIZAPRIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALIZAPRIDE MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALIZAPRIDE MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALIZAPRIDE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALIZAPRIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALIZAPRIDE MARKET SIZE, BY GENERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALIZAPRIDE MARKET SIZE, BY NURSE ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALIZAPRIDE MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ALIZAPRIDE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ALIZAPRIDE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ALIZAPRIDE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ALIZAPRIDE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ALIZAPRIDE MARKET SIZE, BY DAY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ALIZAPRIDE MARKET SIZE, BY INPATIENT SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ALIZAPRIDE MARKET SIZE, BY HYPEREMESIS GRAVIDARUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ALIZAPRIDE MARKET SIZE, BY MORNING SICKNESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. CANADA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 94. CANADA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 95. CANADA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. CANADA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. CANADA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. CANADA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. CANADA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. CANADA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. CANADA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 102. CANADA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 103. CANADA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 104. CANADA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 106. CANADA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 107. CANADA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 122. MEXICO ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 123. MEXICO ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 191. GERMANY ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 192. GERMANY ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. GERMANY ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. GERMANY ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. GERMANY ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. GERMANY ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 197. GERMANY ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. GERMANY ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 200. GERMANY ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. GERMANY ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 202. GERMANY ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 203. GERMANY ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 204. GERMANY ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 205. FRANCE ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 207. FRANCE ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. FRANCE ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. FRANCE ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 211. FRANCE ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. FRANCE ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 213. FRANCE ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. FRANCE ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 216. FRANCE ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. FRANCE ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 218. FRANCE ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 219. FRANCE ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 220. FRANCE ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 237. ITALY ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. ITALY ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 239. ITALY ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 240. ITALY ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. ITALY ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ITALY ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. ITALY ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. ITALY ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. ITALY ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. ITALY ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 247. ITALY ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 248. ITALY ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. ITALY ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 250. ITALY ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 251. ITALY ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 252. ITALY ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 255. SPAIN ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 256. SPAIN ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SPAIN ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SPAIN ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 259. SPAIN ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. SPAIN ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 261. SPAIN ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. SPAIN ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 264. SPAIN ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. SPAIN ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SPAIN ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 267. SPAIN ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 268. SPAIN ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 317. DENMARK ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. DENMARK ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 319. DENMARK ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 320. DENMARK ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 321. DENMARK ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. DENMARK ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 323. DENMARK ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 324. DENMARK ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 325. DENMARK ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. DENMARK ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 327. DENMARK ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 328. DENMARK ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 329. DENMARK ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 330. DENMARK ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 331. DENMARK ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 332. DENMARK ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 339. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 340. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 341. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 343. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 344. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 345. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 346. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 347. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 348. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 349. QATAR ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 350. QATAR ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 351. QATAR ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 352. QATAR ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 353. QATAR ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. QATAR ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 355. QATAR ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 356. QATAR ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 357. QATAR ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 358. QATAR ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 359. QATAR ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 360. QATAR ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 361. QATAR ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 362. QATAR ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 363. QATAR ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 364. QATAR ALIZAPRIDE MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Alizapride market report include:
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.23 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Alizapride (CAS 59338-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Alizapride (CAS 59338-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030 - Product Image

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Chemotherapy Induced Nausea Vomiting Market Report and Forecast 2025-2034 - Product Image

Chemotherapy Induced Nausea Vomiting Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025 - Product Image

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Alizapride Market

Alizapride is a type of gastrointestinal drug used to treat symptoms of gastrointestinal disorders such as nausea, vomiting, and abdominal pain. It is a dopamine antagonist, meaning it blocks the action of dopamine in the brain, which can help reduce nausea and vomiting. Alizapride is available in both oral and injectable forms, and is often used in combination with other medications to treat more severe symptoms. It is also used to treat irritable bowel syndrome and other functional gastrointestinal disorders. Alizapride is a widely used drug in the gastrointestinal market, and is available from many pharmaceutical companies. Some of the companies that produce alizapride include Sanofi, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.